The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Specialty Chemicals grew 38% YoY for FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
